Search by Drug Name or NDC
NDC 00069-2299-30 Vizimpro 45 mg/1 Details
Vizimpro 45 mg/1
Vizimpro is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is DACOMITINIB.
MedlinePlus Drug Summary
Dacomitinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Dacomitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Related Packages: 00069-2299-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Dacomitinib
Product Information
| NDC | 00069-2299 |
|---|---|
| Product ID | 0069-2299_7a7e890e-6637-4aff-b4fd-96815d2f1f3f |
| Associated GPIs | 21360019000340 |
| GCN Sequence Number | 079000 |
| GCN Sequence Number Description | dacomitinib TABLET 45 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 40423 |
| HICL Sequence Number | 045283 |
| HICL Sequence Number Description | DACOMITINIB |
| Brand/Generic | Brand |
| Proprietary Name | Vizimpro |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | dacomitinib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 45 |
| Active Ingredient Units | mg/1 |
| Substance Name | DACOMITINIB |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA211288 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00069-2299-30 (00069229930)
| NDC Package Code | 0069-2299-30 |
|---|---|
| Billing NDC | 00069229930 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0069-2299-30) |
| Marketing Start Date | 2018-10-04 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |